Enter your keyword

A Focused Portfolio Addressing Areas of Unmet Need

Development Pipeline


Platinum-resistant ovarian cancer (prOC)

CA4P + bevacizumab + PCC vs
bevacizumab + PCC (FOCUS)

Phase 2/3

Recurrent ovarian cancer

CA4P + pazopanib (PAZOFOS)

Phase 1b/2

Glioblastoma multiforme (GBM)

CA4P + bevacizumab vs bevacizumab

Phase 2/3 (planning)


Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS)

OXi4503 + cytarabine (OX1222)

Phase 1/2

Preclinical programs are being conducted in the following areas: